BACKGROUND:Cognitive impairment is common in patients with end-stage renal disease receiving hemodialysis 3 times per week. STUDY DESIGN: Randomized clinical trial. SETTING & PARTICIPANTS: 218 individuals participating in the Frequent Hemodialysis Network (FHN) Daily Trial and 81 participating in the FHN Nocturnal Trial. INTERVENTION: The Daily Trial tested in-center hemodialysis 6 times per week versus 3 times per week. The Nocturnal Trial tested home nocturnal hemodialysis 6 times per week versus home or in-center hemodialysis 3 times per week. OUTCOMES: Cognitive function was measured at baseline, month 4, and month 12. The primary outcome was performance on the Trail-Making Test, Form B, a measure of executive function, and a secondary outcome was performance on the Modified Mini-Mental State Examination, a measure of global cognition. The domains of attention, psychomotor speed, memory, and verbal fluency were assessed in 59 participants in the Daily Trial and 19 participants in the Nocturnal Trial. RESULTS: We found no benefit of frequent hemodialysis in either trial for the primary cognitive outcome (Daily Trial: OR for improvement, 0.99; 95% CI, 0.59-1.66; Nocturnal Trial: OR, 1.19; 95% CI, 0.48-2.96). Similarly, there was no benefit of frequent hemodialysis in either trial on global cognition, the secondary cognitive outcome. Exploratory analyses in the Daily Trial suggested possible benefits of frequent hemodialysis for memory and verbal fluency, but not for attention and psychomotor speed. Exploratory analyses in the Nocturnal Trial suggested no benefit of frequent hemodialysis on attention, psychomotor speed, memory, or verbal fluency. LIMITATIONS: Unblinded intervention, small sample. CONCLUSIONS: Frequent hemodialysis did not improve executive function or global cognition. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:Cognitive impairment is common in patients with end-stage renal disease receiving hemodialysis 3 times per week. STUDY DESIGN: Randomized clinical trial. SETTING & PARTICIPANTS: 218 individuals participating in the Frequent Hemodialysis Network (FHN) Daily Trial and 81 participating in the FHN Nocturnal Trial. INTERVENTION: The Daily Trial tested in-center hemodialysis 6 times per week versus 3 times per week. The Nocturnal Trial tested home nocturnal hemodialysis 6 times per week versus home or in-center hemodialysis 3 times per week. OUTCOMES: Cognitive function was measured at baseline, month 4, and month 12. The primary outcome was performance on the Trail-Making Test, Form B, a measure of executive function, and a secondary outcome was performance on the Modified Mini-Mental State Examination, a measure of global cognition. The domains of attention, psychomotor speed, memory, and verbal fluency were assessed in 59 participants in the Daily Trial and 19 participants in the Nocturnal Trial. RESULTS: We found no benefit of frequent hemodialysis in either trial for the primary cognitive outcome (Daily Trial: OR for improvement, 0.99; 95% CI, 0.59-1.66; Nocturnal Trial: OR, 1.19; 95% CI, 0.48-2.96). Similarly, there was no benefit of frequent hemodialysis in either trial on global cognition, the secondary cognitive outcome. Exploratory analyses in the Daily Trial suggested possible benefits of frequent hemodialysis for memory and verbal fluency, but not for attention and psychomotor speed. Exploratory analyses in the Nocturnal Trial suggested no benefit of frequent hemodialysis on attention, psychomotor speed, memory, or verbal fluency. LIMITATIONS: Unblinded intervention, small sample. CONCLUSIONS: Frequent hemodialysis did not improve executive function or global cognition. Published by Elsevier Inc.
Authors: Michael V Rocco; Robert S Lockridge; Gerald J Beck; Paul W Eggers; Jennifer J Gassman; Tom Greene; Brett Larive; Christopher T Chan; Glenn M Chertow; Michael Copland; Christopher D Hoy; Robert M Lindsay; Nathan W Levin; Daniel B Ornt; Andreas Pierratos; Mary F Pipkin; Sanjay Rajagopalan; John B Stokes; Mark L Unruh; Robert A Star; Alan S Kliger; A Kliger; P Eggers; J Briggs; T Hostetter; A Narva; R Star; B Augustine; P Mohr; G Beck; Z Fu; J Gassman; T Greene; J Daugirdas; L Hunsicker; B Larive; M Li; J Mackrell; K Wiggins; S Sherer; B Weiss; S Rajagopalan; J Sanz; S Dellagrottaglie; M Kariisa; T Tran; J West; M Unruh; R Keene; J Schlarb; C Chan; M McGrath-Chong; R Frome; H Higgins; S Ke; O Mandaci; C Owens; C Snell; G Eknoyan; L Appel; A Cheung; A Derse; C Kramer; N Geller; R Grimm; L Henderson; S Prichard; E Roecker; M Rocco; B Miller; J Riley; R Schuessler; R Lockridge; M Pipkin; C Peterson; C Hoy; A Fensterer; D Steigerwald; J Stokes; D Somers; A Hilkin; K Lilli; W Wallace; B Franzwa; E Waterman; C Chan; M McGrath-Chong; M Copland; A Levin; L Sioson; E Cabezon; S Kwan; D Roger; R Lindsay; R Suri; J Champagne; R Bullas; A Garg; A Mazzorato; E Spanner; M Rocco; J Burkart; S Moossavi; V Mauck; T Kaufman; A Pierratos; W Chan; K Regozo; S Kwok Journal: Kidney Int Date: 2011-07-20 Impact factor: 10.612
Authors: Glenn M Chertow; Nathan W Levin; Gerald J Beck; John T Daugirdas; Paul W Eggers; Alan S Kliger; Brett Larive; Michael V Rocco; Tom Greene Journal: J Am Soc Nephrol Date: 2015-10-14 Impact factor: 10.121
Authors: Mark Duncan Findlay; Jesse Dawson; David Alexander Dickie; Kirsten P Forbes; Deborah McGlynn; Terry Quinn; Patrick B Mark Journal: J Am Soc Nephrol Date: 2018-12-07 Impact factor: 10.121
Authors: Manjula Kurella Tamura; Glenn M Chertow; Thomas A Depner; Allen R Nissenson; Brigitte Schiller; Ravindra L Mehta; Sai Liu; Tammy L Sirich Journal: J Am Soc Nephrol Date: 2016-07-21 Impact factor: 10.121